Manufacturing sites in Italy

Innovation and technology, the Italian way

The two Italian production plants represent the quality and excellence of the Made in Italy. With their patented high-tech production lines, they allow IBSA to be one of the main European players active in the production for both the pharmaceutical and the nutritional sector. 


The Lodi plant – Acquired by the Group in 2001, over the years the Lodi plant was subjected to a complete and radical renovation of the existing production areas, which resulted in the creation of a very modern production unit where high-tech lines have been set up for the development of innovative procedures.  

The plant stands on a total area of 12,000 m2 and includes: 12 production departments, the warehouse and the raw material sampling areas, the dispensing department for the preparation of work orders, the Research and Development labs, the Quality Control, Microbiology and Chemistry labs and the Regulatory, Quality Assurance, Production, Engineering and Maintenance offices. The pharmaceutical production area and the raw materials warehouse occupy 5,500 m2, while the nutritional production area, with its dedicated warehouse, occupies a space of 1,000 m2. A total of 224 employees work in the plant. 

The plant produces injectables – both through aseptic processing and terminal sterilization – in traditional vials and in pre-filled syringes, preparations for topical use (creams, gels, solutions) in BoV (Bag-on-Valve) and soft capsules (soft gel). The production lines of the plant are in the forefront in terms of technology and eco-environmental sustainability. The significant investments made in the modernisation of the industrial plants and in the process lines allowed to achieve high standards of efficiency. 

The pharmaceutical products of the Lodi plant serve the IBSA Group and directly supply several markets, including – in addition to Italy – Switzerland, England, Hungary, Slovakia, Czech Republic, Poland, Greece, Spain, the Scandinavian countries, Russia, Egypt, Turkey, the United Arab Emirates, US, Brazil and Korea. 


The Cassina De’ Pecchi plant – Founded in 1994 and acquired by IBSA in 2010, the Cassina De’ Pecchi plant has twenty years of experience in the production of plasters based on diclofenac, fentanyl, nitro-glycerine and pyroxicam. 

In 2017, it started the production of sildenafil with FilmTec® technology in orodispersible film (ODF), and in 2019 also the production of food supplements. IBSA is one of the few European players capable of producing for both the pharmaceutical and the nutritional sector with FilmTec®, a highly innovative technology. 

The plant also produces transdermal medicated plasters based on drug-in-adhesive technology, which allows a controlled release of the drug. The plant stands on a total area of 20,500 m2 and includes research and development labs, its own Quality Control department and the offices. The production areas and the warehouse occupy an area of 5,450 m2, while the plants 3,404 m2. A total of 96 people work in Cassina De’ Pecchi. 

  • Production is concentrated in the following technologies and pharmaceutical forms:  
  • Medicated plasters for topical and transdermal administration 
  • Patches with natural active ingredients for cosmetic and medical device applications 
  • Orodispersible film (ODF) 

The productions of the Cassina plant serve both the IBSA Group and multinational companies, and directly supply several markets, including – in addition to Italy – France, England, Hungary, Slovakia, Czech Republic, Spain, the Baltic Republics, the Scandinavian countries, the EMEA area and South America